Total Payments
$640.43
2024 Payments
$125.39
Companies
12
Transactions
40
Medicare Patients
3,151
Medicare Billing
$192,998
Payment Breakdown by Category
Food & Beverage$598.92 (93.5%)
Education$41.51 (6.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $598.92 | 37 | 93.5% |
| Education | $41.51 | 3 | 6.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $139.19 | 7 | $0 (2024) |
| Incyte Corporation | $109.92 | 7 | $0 (2024) |
| Lilly USA, LLC | $79.27 | 6 | $0 (2024) |
| Dermavant Sciences, Inc. | $67.47 | 4 | $0 (2023) |
| Janssen Biotech, Inc. | $64.76 | 4 | $0 (2024) |
| Amgen Inc. | $48.39 | 3 | $0 (2024) |
| UCB, Inc. | $47.79 | 3 | $0 (2024) |
| Galderma Laboratories, L.P. | $28.72 | 2 | $0 (2022) |
| Kyowa Kirin, Inc. | $15.33 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.15 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125.39 | 7 | Incyte Corporation ($23.40) |
| 2023 | $184.11 | 11 | Dermavant Sciences, Inc. ($53.47) |
| 2022 | $164.18 | 11 | Incyte Corporation ($41.64) |
| 2021 | $166.75 | 11 | Janssen Biotech, Inc. ($48.89) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Immunology | ||||||
| 10/02/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.40 | General |
| Category: Dermatology | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/15/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Monoclonal Antibody | ||||||
| 02/07/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Immunology | ||||||
| 01/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Immunology | ||||||
| 01/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Inflammation | ||||||
| 11/08/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/22/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $15.26 | General |
| Category: Dermatology | ||||||
| 09/07/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Immunology | ||||||
| 08/11/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: DERMATOLOGY | ||||||
| 07/19/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Immunology | ||||||
| 06/15/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: DERMATOLOGY | ||||||
| 06/01/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/04/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $12.83 | General |
| Category: Dermatology | ||||||
| 04/19/2023 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Immunology | ||||||
| 02/22/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: DERMATOLOGY | ||||||
| 02/15/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $12.87 | General |
| 11/28/2022 | Dermavant Sciences, Inc. | VTAMA (Drug) | Education | In-kind items and services | $14.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/10/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.57 | General |
| Category: Immunology | ||||||
| 08/11/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/10/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.15 | General |
| 06/01/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: Immunology | ||||||
| 05/11/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $16.57 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 968 | 1,894 | $371,819 | $58,205 |
| 2022 | 12 | 848 | 1,727 | $312,616 | $52,093 |
| 2021 | 13 | 722 | 1,344 | $254,069 | $45,457 |
| 2020 | 14 | 613 | 1,085 | $222,675 | $37,243 |
Total Patients
3,151
Total Services
6,050
Medicare Billing
$192,998
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 211 | 256 | $66,053 | $12,891 | 19.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 134 | 148 | $62,293 | $8,759 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 117 | $42,559 | $8,737 | 20.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 161 | 203 | $55,748 | $5,931 | 10.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 136 | 863 | $23,819 | $3,739 | 15.7% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 18 | 19 | $23,677 | $3,500 | 14.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 45 | 54 | $25,113 | $3,370 | 13.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 25 | 33 | $22,770 | $3,361 | 14.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 46 | 80 | $16,781 | $2,781 | 16.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 21 | 23 | $12,029 | $1,676 | 13.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $8,617 | $1,565 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,654 | $1,170 | 17.6% |
| 69100 | Biopsy of ear | Office | 2023 | 12 | 13 | $5,167 | $597.00 | 11.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 12 | $330.72 | $100.80 | 30.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 32 | $208.96 | $26.70 | 12.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 167 | 222 | $55,300 | $11,512 | 20.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 107 | 117 | $49,245 | $7,669 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 89 | $31,456 | $6,546 | 20.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 156 | 193 | $51,404 | $5,724 | 11.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 37 | 42 | $28,111 | $4,340 | 15.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 134 | 840 | $22,025 | $3,566 | 16.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 55 | 55 | $16,854 | $3,533 | 21.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 41 | 83 | $17,754 | $2,957 | 16.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $10,071 | $2,132 | 21.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 24 | 24 | $12,652 | $1,959 | 15.5% |
About Jeffrey Weideman, PA-C
Jeffrey Weideman, PA-C is a Medical healthcare provider based in Saint Peter, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1013149079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jeffrey Weideman, PA-C has received a total of $640.43 in payments from pharmaceutical and medical device companies, with $125.39 received in 2024. These payments were reported across 40 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($598.92).
As a Medicare-enrolled provider, Weideman has provided services to 3,151 Medicare beneficiaries, totaling 6,050 services with total Medicare billing of $192,998. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical
- Location Saint Peter, MN
- Active Since 08/10/2009
- Last Updated 07/15/2020
- Taxonomy Code 363AM0700X
- Entity Type Individual
- NPI Number 1013149079
Products in Payments
- DUPIXENT (Biological) $139.19
- OPZELURA (Drug) $109.92
- TALTZ (Drug) $79.27
- VTAMA (Drug) $67.47
- TREMFYA (Drug) $64.76
- Otezla (Drug) $48.39
- Cimzia (Drug) $30.92
- Bimzelx (Biological) $16.87
- AKLIEF (Drug) $15.34
- Poteligeo (Drug) $15.33
- ORACEA (Drug) $13.38
- Sotyktu (Drug) $12.57
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.